52 related articles for article (PubMed ID: 17931705)
21. The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease.
Prediger RD; Batista LC; Medeiros R; Pandolfo P; Florio JC; Takahashi RN
Exp Neurol; 2006 Dec; 202(2):391-403. PubMed ID: 16908021
[TBL] [Abstract][Full Text] [Related]
22. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets.
Iravani MM; Syed E; Jackson MJ; Johnston LC; Smith LA; Jenner P
Eur J Neurosci; 2005 Feb; 21(4):841-54. PubMed ID: 15787691
[TBL] [Abstract][Full Text] [Related]
23. Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease.
Reksidler AB; Lima MM; Dombrowski P; Andersen ML; Zanata SM; Andreatini R; Tufik S; Vital MA
J Neurosci Methods; 2008 Jan; 167(2):268-77. PubMed ID: 17931705
[TBL] [Abstract][Full Text] [Related]
24. The MPTP model of Parkinson's disease.
Smeyne RJ; Jackson-Lewis V
Brain Res Mol Brain Res; 2005 Mar; 134(1):57-66. PubMed ID: 15790530
[TBL] [Abstract][Full Text] [Related]
25. [Experimental models, of Parkinson disease].
Luquin MR
Rev Neurol; 2000 Jul 1-15; 31(1):60-6. PubMed ID: 10948587
[TBL] [Abstract][Full Text] [Related]
26. Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease?
Morale MC; L'Episcopo F; Tirolo C; Giaquinta G; Caniglia S; Testa N; Arcieri P; Serra PA; Lupo G; Alberghina M; Harada N; Honda S; Panzica GC; Marchetti B
Brain Res Rev; 2008 Mar; 57(2):431-43. PubMed ID: 18063054
[TBL] [Abstract][Full Text] [Related]
27. [Experimental models of Parkinson's disease].
Féger J; Pessigliore M; François C; Tremblay L; Hirsch E
Ann Pharm Fr; 2002 Jan; 60(1):3-21. PubMed ID: 11976545
[TBL] [Abstract][Full Text] [Related]
28. Experimental models of Parkinson's disease: insights from many models.
Tolwani RJ; Jakowec MW; Petzinger GM; Green S; Waggie K
Lab Anim Sci; 1999 Aug; 49(4):363-71. PubMed ID: 10480640
[TBL] [Abstract][Full Text] [Related]
29. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates.
Jakowec MW; Petzinger GM
Comp Med; 2004 Oct; 54(5):497-513. PubMed ID: 15575363
[TBL] [Abstract][Full Text] [Related]
30. Altered gene expression profiles reveal similarities and differences between Parkinson disease and model systems.
Miller RM; Federoff HJ
Neuroscientist; 2005 Dec; 11(6):539-49. PubMed ID: 16282595
[TBL] [Abstract][Full Text] [Related]
31. [Pathophysiology of Parkinson's disease: an update].
Tremblay L
Bull Acad Natl Med; 2010 Oct; 194(7):1321-31; discussion 1331-2. PubMed ID: 22043627
[TBL] [Abstract][Full Text] [Related]
32. [Parkinson's disease; etiology and animal model].
Mizuno Y
No To Shinkei; 1991 Aug; 43(8):703-11. PubMed ID: 1931253
[No Abstract] [Full Text] [Related]
33. Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol.
Meredith GE; Totterdell S; Potashkin JA; Surmeier DJ
Parkinsonism Relat Disord; 2008; 14 Suppl 2(Suppl 2):S112-5. PubMed ID: 18585085
[TBL] [Abstract][Full Text] [Related]
34. The neurobiology of the substantia nigra pars compacta: from motor to sleep regulation.
Lima MM; Reksidler AB; Vital MA
J Neural Transm Suppl; 2009; (73):135-45. PubMed ID: 20411774
[TBL] [Abstract][Full Text] [Related]
35. [Neuropathology of the basal ganglia in Parkinson's disease with a special reference to its responsible lesion].
Tanaka J; Fukuda T
Nihon Rinsho; 1997 Jan; 55(1):32-8. PubMed ID: 9014420
[TBL] [Abstract][Full Text] [Related]
36. The effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on the cognitive and motor functions in rodents: A systematic review and meta-analysis.
Narmashiri A; Abbaszadeh M; Ghazizadeh A
Neurosci Biobehav Rev; 2022 Sep; 140():104792. PubMed ID: 35872230
[TBL] [Abstract][Full Text] [Related]
37. [Neurotoxin candidates as pathogenic agents of Parkinson's disease].
Naoi M
No To Shinkei; 1997 Sep; 49(9):793-803. PubMed ID: 9310995
[No Abstract] [Full Text] [Related]
38. The MPTP tale: pathway to prevention of Parkinson's disease?
Williams A; Waring R
Br J Hosp Med; 1993 May 19-Jun 1; 49(10):716-9. PubMed ID: 8324592
[TBL] [Abstract][Full Text] [Related]
39. Dynamic Changes in the Nigrostriatal Pathway in the MPTP Mouse Model of Parkinson's Disease.
Huang D; Xu J; Wang J; Tong J; Bai X; Li H; Wang Z; Huang Y; Wu Y; Yu M; Huang F
Parkinsons Dis; 2017; 2017():9349487. PubMed ID: 28831326
[TBL] [Abstract][Full Text] [Related]
40. MPTP: insights into the etiology of Parkinson's disease.
Langston JW
Eur Neurol; 1987; 26 Suppl 1():2-10. PubMed ID: 3556187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
